The 4 most recent market catalysts affecting $EDIT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 65
This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
The filing reports multiple analyst upgrades across different companies. For Editas Medicine (EDIT), Guggenheim upgraded the stock from Neutral to Buy with a $5 price target, a sig…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target
Guggenheim analyst Debjit Chattopadhyay upgraded Editas Medicine (EDIT) from Neutral to Buy and established a $5 price target. This upgrade signals increased confidence from a prom…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 55
Editas Medicine Files Prospectus For Offering $400M Mixed Shelf
Editas Medicine filed a mixed shelf offering prospectus, which is a standard regulatory step allowing a company to issue various types of securities (like common stock, preferred s…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 92
Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate
Editas Medicine (EDIT) announced Q2 earnings per share of $(0.15), significantly beating the analyst estimate of $(0.27), and sales of $11.900 million, far exceeding the $2.800 mil…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.